18129-Lung Cancer-NA-547

Lung Cancer

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG�)Versus Alectinib (ALECENSA�) in Advanced Anaplastic Lymphoma Kinase-Positive Non�Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI�)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number:

  • Address

310 Smith Ave N
Suite 100
Saint Paul, MN 55102
P: (651) 251-5500

Search by practice name, trial titles, indicators and specific disease types.